Inhaled budesonide for COVID-19 in people at higher risk of complications in the community: the UK National Community Randomi
<p><strong>Background:</strong> The effectiveness of repurposed treatments with supportive evidence for higher risk individuals with COVID-19 in the community is unknown. In the UK PRINCIPLE national platform trial we aimed to determine whether 're-purposed medicines' (hy...
Main Authors: | Gbinigie, O, Ogburn, E, Yu, L-M, van Hecke, O, Dorward, J, Butler, C, Saville, B |
---|---|
Format: | Conference item |
Language: | English |
Published: |
Annals of Family Medicine
2023
|
Similar Items
-
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: Yu, L-M, et al.
Published: (2021) -
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
by: Yu, L-M, et al.
Published: (2021) -
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: Butler, CC, et al.
Published: (2021) -
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: PRINCIPLE Trial Collaborative Group, et al.
Published: (2021) -
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
by: Hayward, G, et al.
Published: (2021)